KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $1.5 billion.

  • Bio-Rad Laboratories' Cash & Current Investments fell 743.77% to $1.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year decrease of 743.77%. This contributed to the annual value of $1.5 billion for FY2025, which is 743.77% down from last year.
  • According to the latest figures from Q4 2025, Bio-Rad Laboratories' Cash & Current Investments is $1.5 billion, which was down 743.77% from $1.4 billion recorded in Q3 2025.
  • Bio-Rad Laboratories' Cash & Current Investments' 5-year high stood at $2.1 billion during Q1 2022, with a 5-year trough of $869.9 million in Q4 2021.
  • Over the past 5 years, Bio-Rad Laboratories' median Cash & Current Investments value was $1.6 billion (recorded in 2024), while the average stood at $1.6 billion.
  • In the last 5 years, Bio-Rad Laboratories' Cash & Current Investments surged by 10584.2% in 2022 and then tumbled by 1499.25% in 2025.
  • Quarter analysis of 5 years shows Bio-Rad Laboratories' Cash & Current Investments stood at $869.9 million in 2021, then soared by 105.84% to $1.8 billion in 2022, then fell by 10.25% to $1.6 billion in 2023, then rose by 3.57% to $1.7 billion in 2024, then dropped by 7.44% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q4 2025, $1.4 billion for Q3 2025, and $1.4 billion during Q2 2025.